Pharmaceutical

ImmunoGen

$8.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.73 (+10.12%) Today
+$0.14 (+1.76%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ImmunoGen and other stocks, options, and ETFs commission-free!

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA. The listed name for IMGN is ImmunoGen, Inc. Common Stock.

CEO
Mark J. Enyedy
Employees
75
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
1.51B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.61M
High Today
$8.10
Low Today
$7.24
Open Price
$7.34
Volume
3.28M
52 Week High
$8.10
52 Week Low
$1.95

Collections

IMGN Earnings

-$0.33
-$0.21
-$0.09
$0.03
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 12, Pre-Market

You May Also Like

ECF-A
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure